Biotechnology - Biotechnology, Sanofi

Filter

Current filters:

BiotechnologySanofi

Popular Filters

1 to 25 of 112 results

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

13-02-2015

French pharma major Sanofi subsidiary Genzyme has reported positive extension study data from its Phase…

BiotechnologyCerdelgaGenzymeRare diseasesResearchSanofi

Voyager inks up to $845 million deal with Genzyme on novel CNS products

Voyager inks up to $845 million deal with Genzyme on novel CNS products

12-02-2015

US gene therapy start-up company Voyager Therapeutics has entered into a major strategic collaboration…

BiotechnologyGenzymeLicensingNeurologicalResearchSanofiUSAVoyager Therapeutics

Regeneron sees strong Eylea sales; financials beat expectations

Regeneron sees strong Eylea sales; financials beat expectations

10-02-2015

US biotech firm Regeneron Pharmaceuticals today announced financial results for the fourth quarter and…

BayerBiotechnologyEyleaFinancialOphthalmicsRegeneron PharmaceuticalsSanofi

Sanofi and Regeneron’s Praluent BLA gains priority review from US FDA

26-01-2015

The US Food and Drug Administration has accepted for priority review the Biologics License Application…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabPraluentRegeneron PharmaceuticalsRegulationSanofiUSA

Sanofi granted European marketing authorization for Cerdelga in Gaucher disease

Sanofi granted European marketing authorization for Cerdelga in Gaucher disease

22-01-2015

French drug major Sanofi and its subsidiary Genzyme have been granted marketing authorization by the…

BiotechnologyCerdelgaGeneticsGenzymeRegulationSanofi

EMA accepts Sanofi and Regeneron's MMA for Praluent for review

EMA accepts Sanofi and Regeneron's MMA for Praluent for review

12-01-2015

French drug major Sanofi and US biotech company Regeneron have announced that the European Medicines…

alirocumabBiotechnologyCardio-vascularEuropeRegeneronRegulationSanofi

Sanofi and Regeneron’s alirocumab meets endpoints in cholesterol study

Sanofi and Regeneron’s alirocumab meets endpoints in cholesterol study

09-01-2015

French pharma major Sanofi and Regeneron Pharmaceuticals today announced that two new ODYSSEY trials,…

alirocumabBiotechnologyCardio-vascularRegeneron PharmaceuticalsResearchSanofi

US sales of Sanofi/Regeneron’s dupilumab for atopic dermatitis could exceed $1.3 billion by 2022, says analyst

04-12-2014

The first biologic to treat atopic dermatitis, French pharma major Sanofi (Euronext: SAN) and US biotech…

BiotechnologyDermatologicalsdupilumabMarkets & MarketingRegeneron PharmaceuticalsSanofiUSA

Regeneron and Sanofi granted breakthrough designation for dupilumab

Regeneron and Sanofi granted breakthrough designation for dupilumab

25-11-2014

US biotech Regeneron Pharmaceuticals and French pharma major Sanofi have said that the US Food and Drug…

BiotechnologyDermatologicalsdupilumabRegeneronRegulationSanofiUSA

Positive Ph III results for Relypsa’s patiromer FOS for hyperkalemia

22-11-2014

US biotech firm Relypsa announced that positive results from the pivotal Phase III program of the company's…

BiotechnologyNephrology and HepatologypatiromerRelypsaRenagelRenvelaResearchSanofiZS PharmaZS-9

Sanofi and Regeneron’s dupilumab gets Breakthrough designation from FDA

20-11-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation to French pharma major…

BiotechnologyDermatologicalsdupilumabRegeneronRegulationSanofiUSA

Sanofi and Regeneron's alirocumab achieves positive Phase III results in reducing LDL

Sanofi and Regeneron's alirocumab achieves positive Phase III results in reducing LDL

19-11-2014

French drug major Sanofi and partner Regeneron Pharmaceuticals have reported results of six Phase III…

alirocumabBiotechnologyGastro-intestinalsRegeneron PharmaceuticalsResearchSanofi

Kynamro achieves significant reduction in MACE

19-11-2014

A retrospective analysis has shown that patients treated with Kynamro (mipomersen sodium) injection for…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroResearchSanofi

FDA at last approves Genzyme’s Lemtrada

FDA at last approves Genzyme’s Lemtrada

15-11-2014

The US Food and Drug Administration on Friday approved French pharma major Sanofi subsidiary Genzyme’s…

BayerBiotechnologyGenzymeLemtradaNeurologicalRegulationSanofiUSA

Regeneron third-qtr net profit plunges despite strong sales growth

Regeneron third-qtr net profit plunges despite strong sales growth

04-11-2014

US biotech firm Regeneron posted revenue of $725.8 million for the third quarter of 2014, a rise of 22%…

alirocumabBayerBiotechnologydupilumabEyleaFinancialOphthalmicsRegeneronResearchSanofisarilumab

Amgen sues Sanofi and Regeneron over alleged patent infringement

19-10-2014

USA-based Amgen has filed a law suit in the US District Court of Delaware against French pharma major…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabLegalPatentsRegeneron PharmaceuticalsSanofiUSA

Selecta, JDRF and Sanofi collaborate to develop SVP for type 1 diabetes

Selecta, JDRF and Sanofi collaborate to develop SVP for type 1 diabetes

17-10-2014

US clinical-stage biopharma company Selecta Biosciences and JDRF have extended their joint research collaboration…

BiotechnologyDiabetesFranceResearchSanofiSelecta BiosciencesUSA

Genzyme collaborates on gene therapy for rare disease that causes childhood blindness

Genzyme collaborates on gene therapy for rare disease that causes childhood blindness

25-09-2014

French pharma major Sanofi subsidiary Genzyme has entered into a research collaboration with the USA’s…

BiotechnologyFranceGenzymeOphthalmicsRare diseasesSanofi

Nanobiotix expands into USA with office in Boston life sciences cluster

Nanobiotix expands into USA with office in Boston life sciences cluster

22-09-2014

France-based Nanobiotix, a clinical-stage nanomedicine company pioneering novel approaches for the local…

BiotechnologyFinancialFranceNanobiotixOncologySanofiUSA

Positive results from four pivotal alirocumab trials at ESC Congress

Positive results from four pivotal alirocumab trials at ESC Congress

31-08-2014

French pharma major Sanofi and US partner Regeneron Pharmaceuticals have announced detailed positive…

alirocumabBiotechnologyCardio-vascularRegeneron PharmaceuticalsResearchSanofi

Genzyme’s Cerdelga gets FDA approval for Gaucher disease

Genzyme’s Cerdelga gets FDA approval for Gaucher disease

20-08-2014

The US Food and Drug Administration late yesterday approved Cerdelga (eliglustat) for the long-term treatment…

ActelionBiotechnologyCerdelgaCerezymeGenzymeRare diseasesRegulationSanofiUSAZavesca

Sanofi and PATH the first to bring large quantities of semisynthetic artemisinin antimalarial treatment to market

Sanofi and PATH the first to bring large quantities of semisynthetic artemisinin antimalarial treatment to market

12-08-2014

French drug major Sanofi and Seattle-based PATH have become the first to deliver large-scale batches…

Anti-viralsartemisininBiotechnologyMarkets & MarketingPATHSanofiUSA

FDA expands approval of Genzyme’s Lumizyme to treat Pompe disease

FDA expands approval of Genzyme’s Lumizyme to treat Pompe disease

02-08-2014

The US Food and Drug Administration on Friday approved Lumizyme (alglucosidase alfa) for treatment of…

BiotechnologyGenzymeLumizymeMyozymeRare diseasesRegulationSanofiUSA

1 to 25 of 112 results

COMPANY SPOTLIGHT

Menarini

Back to top